Skyhawk's FALCON-HD trial has dosed the first participants in the US with the drug, SKY-0515. The once-daily pill targets two drivers of HD, but does it actually slow disease? That's the big question this study hopes to answer.

The FDA has accepted uniQure's application for AMT-130, an experimental gene therapy for Huntington's disease, and set a May 2027 decision date. Here's what this milestone means, and what still needs to happen.

From sticky thoughts and pigs that model HD to DNA repair and promising drug trial results, October brought fresh insights into HD. Here's what you might have missed!